Management of glaucoma associated with aniridia

John Brookes

Talk by Mr John Brookes, Moorfields Eye Hospital, at Conference 2025

A presentation about aniridia issues, particularly regarding how glaucoma is treated in children and adults with aniridia, from medical to laser and surgery.

Mr Brookes trained in London and qualified in 1993, subsequently specialising in ophthalmology and further, in paediatric glaucoma, for which he has been a consultant at Moorfields Eye Hospital since 2004. His main interest is in secondary glaucomas in children, such as aniridia and their surgical management.

Transcript

[James] Fantastic to have with us now John Brookes, who is also one of our medical advisors for Aniridia Network, recently appointed. Take it away John, thank you very much.

[John] Thank you very much. So thank you for the very kind invitation to come and talk to you today.

So just a bit about me, I’m a consultant at Moorfields Eye Hospital, which I have been for about 22 years, and I also work at the Royal Victoria Hospital in Belfast, and so I spend a day a week in Belfast seeing all the children from Northern Ireland with glaucoma. So I deal with the whole range of paediatric glaucoma. So I’m going to talk a little bit about what my experience is in treating children with aniridic glaucoma.

So as you know aniridia is quite a rare condition. It was first described by somebody called Barratta in 1818. I’ve tried to find out who Barratta is, but have been unsuccessful, but he described it quite a long time ago.

It’s a bilateral condition, as you know, so it affects both eyes. And it’s a pan-ophthalmic disorder, so it’s not only the iris that is involved in the condition. And obviously I’ll show the other clinical effects that aniridia can cause in children.

It’s rare, so it’s estimated to affect between one in 40 to one in 100,000 children. And I’m going to really concentrate this talk on dealing with children, which is what I deal with on a daily basis.

You can see on the clinical photographs on the left, total aniridia, and obviously there are variable degrees of iris hypoplasia. So hypoplasia is an underdevelopment of the iris. And these two photographs show total aniridia. So there’s a complete absence of the iris.

And on the upper slide, you can see these little bobbles here, which are called the ciliary processes, and we’ll come back to those. These are the parts of the eye that manufacture aqueous. This is the fluid that fills the front part of the eye. And that’s very important when we’re talking about raised intraocular pressure, which is what we need to deal with when we’re talking about glaucoma.

I’m sure you’ll have heard about this from Professor Moosajee earlier on this afternoon, that about 85% of cases are familial. So these are autosomal dominant cases. So that means that you only need to inherit one faulty gene from a parent to exhibit the disease itself.

About 15% of cases are thought to be sporadic, so there’s no family history. And it’s important because, as you know, these can be associated with other systemic problems, such as Wilms tumour.

You can see on the lower slide here, this is a case of aniridia, but only partial aniridia. So the absence of the iris is only in the upper part of the eye there. And again, this top slide’s total aniridia. And you can see the ciliary processes, which are the cells that produce the aqueous humour. The incidence of aniridia is the same in boys and girls.

Obviously, photosensitivity is a very important symptom of aniridia. And you can see this child has to have very dark glasses to cope with his photophobia. And we couldn’t really take them off him to have a look at his eyes until he was under general anaesthetic.

But there’s a variety of eye conditions that can stem from aniridia. Nystagmus is an involuntary jerking movement of the eye that happens in children with poor vision from very early on.

Squint is a non-alignment of the eyes, so one eye turns inwards or outwards. That’s usually because of a condition called amblyopia, otherwise a lazy eye. Because children, as they’re developing their vision, often in medical conditions, often have one eye that’s a little bit stronger and sees better than the fellow eye. And if that happens, then the fellow eye, the brain connections don’t develop normally. So they ignore all the vision from the poorer eye. And that’s called a lazy eye or amblyopia. And we have to patch the good eye, the better-seeing eye, to force the fellow eye to start seeing a bit better, to strengthen it up.

And these conditions, squints, amblyopia, refractive errors, are very common in aniridia.

One of the very big problems for vision reasons in aniridia is corneal pannus. This is a progressive fibrovascular scarring around the cornea that affects the peripheral cornea that can spread more centrally.

This is due to the absence of what we call limbal stem cells. So these are specialised cells that develop into corneal epithelial cells. And there’s an absence of this in aniridia. So instead of the clear cornea regenerating itself, the scar tissue replaces it and that can have a very big effect on vision.

It’s also very difficult to treat this, because if it gets to a stage where it needs a corneal transplant, for example, because of the vascularisation of the abnormal blood vessels, that can make the rejection of a new cornea much more likely. So corneal transplants often fail, I’m afraid, in aniridia because of this problem.

Cataracts are very common in aniridia. They account for about 85% cases of aniridia. And we often have to carry out cataract surgery to improve people’s vision.

Optic nerve and foveal hypoplasia, and certainly foveal hypoplasia is almost universal in aniridia. And this is an underdevelopment of the fovea, which is the central part of the retina, which deals with the very fine focusing. And this is the reason why children in infancy have poor vision. Poor vision happens in aniridia in older age because of either cataract, corneal problems or glaucoma.

And this is obviously my main focus. And about 50% of children with aniridia may well develop glaucoma. And it’s probably one of the most important aspects of aniridia to talk about, because this is the condition that is irreversible. Other conditions within aniridia can be treated. And glaucoma can certainly be treated and stabilised, but any damage that happens from glaucoma is irreversible.

A couple of syndromes in aniridia you may well have heard of. WAGR, that occurs because of a deletion on a particular chromosome – chromosome 11. And it’s thought to account for about 30% of sporadic cases of aniridia.

And this is the importance of referring children to paediatricians because we need to screen for Wilms tumour, and do the genetic testing that Professor Moosajee would have talked about earlier.

Gillespie syndrome is quite a rare syndrome associated with aniridia, and this accounts for about 2% of cases of aniridia. And this is an autosomal recessive disease. And so both parents need to be carriers for an affected child to develop Gillespie syndrome. And so one faulty gene needs to be acquired from each parent. But importantly, this is not associated with Wilms tumour.

So I normally go through talks and go through consultations and see children for 10/15 years. And I think the parents and the children know everything about glaucoma. And then somebody will say “What exactly is glaucoma?” So I thought we’d just address that issue first.

It’s an interesting definition, really, because at the end of the day, glaucoma is a disease of the optic nerve. And if you’re in glaucoma clinics, you’ll be very obsessed by intraocular pressure. But in fact, you don’t need to have a high intraocular pressure to have glaucoma.

So glaucoma is an optic neuropathy. So it’s a disease that affects the optic nerve. Now having said that, all children’s types of glaucoma – aniridia, and all other types of paediatric glaucoma – only occur when a child has a high intraocular pressure. And we’ll talk about why that might happen in a minute.

Now, adults can have glaucoma even with a normal eye pressure. But if an adult with aniridia has glaucoma, it’s usually associated with a high intraocular pressure.

And you can see in the clinic, there are different types of measuring the eye pressure, depending on the age and the cooperation of the child. So this is what we call an eye care tonometer. It revolutionised how we manage children, because often we’ve very often had to put children under general anaesthetics to measure their eye pressure. Whereas this eye care is much more acceptable for children and they’re much more cooperative in having it done, having the pressures checked in the clinic.

As they grow up a little bit, we use Goldmann tonometry. And this is a more gold standard type of measurement. So it’s a more accurate measurement of intraocular pressure.

And all our treatments for glaucoma all relate to reducing the intraocular pressure. Whether that’s with medicine, whether it’s with a laser or whether it’s with surgery.

Now when we’re looking at optic nerves, you can see these two photographs on the bottom here. So this is a healthy optic nerve. Why is it healthy? Well, I always describe it as when we’re looking into the back of somebody’s eye, we’re looking at the end of the optic nerve.

So the optic nerve is a stalk. It’s a bundle of over a million individual nerve fibres that connects the eye to the brain. The end of the optic nerve essentially looks like a polo mint. There’s the minty part, which we call the rim, and there’s a hole in the middle.

So here you can see that the pink area is the mint and there’s a paler hole in the middle. And in this photograph, you can see the hole is much bigger and the rim is much thinner. So it’s like you’ve been sucking a polo mint for a long time.

And what we’re looking for is this hole in the middle progressively enlarging. And that’s what we see with glaucoma damage. You’re losing nerve tissue, so the hole in the middle is getting bigger and the rim is getting smaller because of damaged nerve fibres.

The consequence of this is that it damages the peripheral vision. And you can see that one of the tests that we often do are called visual field tests. And there are very characteristic patterns of visual field loss in people with glaucoma.

So essentially, the intraocular pressure increases, that damages the optic nerve, that affects the visual field, and that’s glaucoma.

Well, why does it happen in people with aniridia? Well, in children, it can happen in infancy, although this is much less common than happening at an older age group. If it does happen in infants, it’s because the angle – and I’ll talk about this shortly – has not developed normally.

Now, the angle is where the drainage channel is and fluid, which is continuously made inside the eye, drains out through a little channel in the eye called the angle. And when that hasn’t developed properly, fluid can’t drain out of the eye. It builds up in the front part of the eye and that increases the eye pressure.

The more common type of mechanism for glaucoma happens in older children or in adults. And that’s what we call angle closure glaucoma. Now, even in cases of total aniridia, even if the iris is completely absent, clinically, there is always some rudimentary tissue of iris, which progressively blocks the angle.

So the angle closes, and this is why we call it angle closure. So there’s a blockage to the fluid draining out of the eye, that causes a build-up of pressure, damages the nerve, and that’s how we get glaucoma.

Now with treatments – and we’re talking really the treatment of any type of glaucoma, and there are literally hundreds of different types of glaucoma in children – there are always three options for treatment: medical, laser, and surgical treatments.

And so what we like to do is start at the lower part of that stepwise ladder of increasing invasiveness, and start with medication. And there are multiple treatments now available in the form of eye drops to reduce intraocular pressure, and I’m sure some of you will have heard of these.

Basically, what they’re doing is that some of them are reducing the amount of aqueous produced inside the eye. So remember, I showed those ciliary processes. These are the cells that make the aqueous. Some of these eye drops affect the ciliary processes to reduce the amount of aqueous that’s made inside the eye. Some of the drops increase how much fluid drain out of the eye.

So Latanoprost, which is a very common one, increases how much fluid drains out of the eye. Timolol, which is an extremely common eye drop for glaucoma, reduces the amount of aqueous that’s made inside the eye.

There are increasingly useful eye drops, which are combinations of drops. So Azarga, Cosopt, these are medications that have two drugs in them. And it’s usually one drug that reduces aqueous production and another drug that increases outflow, and they’re mixed together.

And we have lots of drops nowadays, which are especially useful in children, with the combination drops, where they only have to be used once a day. And they also lack preservatives, and these preservatives are chemicals that keep the drop from getting infections in them. But they’re much more comfortable to use when they don’t have preservatives in them. And these are especially useful for children, because they’re comfortable in general, and they only have to be used once a day.

So we would start with one drop, maybe add a drop, or change a drop. And so we’ve got multiple different combinations of medication, before we think about having to move up to the next stage of treatment.

How often do we need to proceed to surgery? Now, as I mentioned, there’s loads of different types of glaucoma in children, and these are the most common types that we see.

The most common childhood glaucoma is called primary congenital glaucoma. So this is the most common glaucoma that we see in infants. And if we diagnose a child with congenital glaucoma, almost all these children will need an operation, because medication is never sufficient to control the intraocular pressure.

All other types of glaucoma, including aniridia, are called secondary glaucomas. And you can see that even though it’s not quite as high as 98%, the majority of children when they’re diagnosed with glaucoma need an operation. And children with aniridia, about 67% of these children, once diagnosed with aniridia, will need surgery at some stage in their lifetime.

Now, you may wonder why I put a cartoon of somebody in a bathtub, because what I want to try and do when I’m trying to explain the surgical treatment is just use a bathtub to try and explain how these surgical operations work.

So if you think of the eyeball like a bathtub, there’s a tap that’s pouring water into the eye, and there’s a plug hole which is draining water out of the eye.

Glaucoma and raised intraocular pressure is when there’s an imbalance between how much water is being poured into the bathtub and how much is draining out. And so, if the plug hole is blocked, the pressure increases. If the tap just continues pouring out fluid and it’s not draining away, the intraocular pressure increases.

So when we’re talking about surgical treatment, or treatment in general, we’re trying to either turn off the tap to have less fluid filling the bathtub, or we’re trying to unblock the plug hole, or find a new way of draining the fluid out of the eyeball.

Now, the treatments can be challenging because glaucoma in children especially is difficult to treat for a whole number of different reasons. It’s difficult because obviously examining babies is difficult and getting accurate pressure readings. It’s difficult trying to get eye drops into children. It’s difficult when you have to operate on them, because they’re not that keen on coming into hospital for surgery, and then they have to use drops very frequently after surgery. So it’s not without its problems.

And if we’ve tried medical treatment, then our next two options are laser treatment or surgery. Now, I’ve listed some of the most common surgical operations that are done for glaucoma in children.

So, angle surgery. This is directly addressing where the abnormality is. It’s the angle, the channel which drains fluid out of the eye. And the operation that we commonly do nowadays is called a trabeculotomy. So, this is where we can open up the channel using a special instrument, which I’ll show you in a moment.

Or a goniotomy, which is slightly out of date now, but a goniotomy is a way of making an incision into the channel to open it up and allowing more fluid to drain out of the eye.

A trabeculectomy is where we’re making a new pathway for draining fluid. We’re making a little hole in the white part of the eye, so there’s a way for fluid to escape.

Glaucoma drainage devices are increasingly commonly used nowadays. It’s probably the most common surgical treatment, otherwise known as tube implants or tube surgery. These are tubes that basically drain the fluid out of the eye continuously. The tube is stitched into the eye. Patients don’t feel it, they don’t see it. But this continually drains fluid out of the eye to lower the intraocular pressure.

So, angle surgery, a little instrument passes through the cornea and makes an incision into the channel to open it up. You can see here, this is a trabeculectomy. So this is done at the top part of the eye. And so the fluid drains out through a little hole that’s made and collects in a little blister on the top of the eye here. And as the pressure goes up, more fluid drains into that little blister and then drains into the circulation.

This is a little catheter which is passed into Schlemm’s canal. Schlemm’s canal is the drainage channel. And when it’s passed into Schlemm’s canal, we can dilate it or open it up to restore that normal drainage.

And this is an example of a type of tube implant. This is called a Baerveldt tube. And you can see that the tube is attached to a large plate. Now, this plate is stitched around the back part of the eye. And then the tube comes forward and the tip of the tube sits just behind the cornea. And as the pressure builds up, the aqueous fluid drains up the tube, collects on top of the plate and then gets reabsorbed into the circulation.

Laser treatment does have an important place in treating glaucoma in children, because it’s a stopgap between the medical treatment of the eye drops and the surgical treatment.

Now, when we’re thinking about surgery and the time when we need to operate, what we’re trying to do is postpone surgery as long as we safely can, because surgical success tends to be increased the older the child is when they have surgery. And when we’re dealing with a lifelong condition, and we’re dealing with operations that are never going to last a lifetime, we want to try and postpone the need for surgery, to stop us getting onto that slippery slope.

And if medical treatment’s not working, cyclodiode laser is a very good option before progressing onto surgery. And what we’re doing with this probe that’s attached to a laser, is that the laser is damaging the ciliary processes which make the aqueous humour. So if you reduce the amount of aqueous humour being produced, then you reduce the amount of fluid, lower the intraocular pressure.

The problem with cyclodiode laser is that it’s only ever seen as a temporary solution, because what will happen is that you destroy the ciliary processes, reduce the pressure, but these ciliary processes will regenerate and then they’ll start pumping aqueous fluid out again. So the pressure will go up. But if this buys some time, then it may be better to operate on a two-year-old than it is on a one-year-old. So it just gives time for the child to get a little bit older before you start surgical treatments.

And the tube implant is one of our mainstays of treatment. So here in these cartoons, you can see how they work. So you can see the plate attached to the tube here, and on this one as well. So the fluid drains along that tube onto the top of the plate, and then gets reabsorbed into the circulation.

There are several different designs of tubes. This is called the Baerveldt tube, and the newer one is called a Paul tube. And the main complication with tube implants is that we don’t want the pressure to drop too low.

Now that sounds a bit odd, but low pressure is actually just as harmful as a high pressure. Because there has to be a certain level of pressure inside the eyeball to keep the eyeball functioning correctly, and keep the retina from detaching or developing any swelling within the retina. So there has to be a lower limit of how low the pressure comes.

And what we do when we’re doing these operations is that we pass a little stitch down the middle of the tube implant, like a little pipe cleaner. So it helps restrict how much fluid is draining up that tube, and that stops the pressure from dropping too low.

But it’s also useful because if in the future the pressure starts to increase again, then that little stitch can simply be pulled out. That allows more fluid to drain along the tube, thus lowering the intraocular pressure.

So we often carry out tube implants. They’re not without other risks, and the particular risk in children and adults with aniridia is that the end of the tube sits behind the cornea. But because there’s an absence of the iris, the lens of the eye is in very close proximity to the tip of the tube implant. And if the tip of the tube is in contact with the lens, that can develop a cataract or can make a cataract worse, and then that might need surgical treatment to remove the cataract.

There has been in recent years, and less so recently in artificial irises, and there are lots of implants which try and replace the iris or give an artificial iris appearance, to try and limit photosensitivity.

I exclusively deal with glaucoma, and these are not a good idea really in children or any adults with glaucoma, because it can actually make glaucoma worse. And even if somebody with aniridia doesn’t have glaucoma, there’s a much increased risk of them subsequently developing glaucoma with these artificial irises. And so this is something that we don’t practice anymore.

So just to summarise, glaucoma secondary to aniridia can be a challenge. That’s not specific to aniridia, it can be challenging for all children with glaucoma. But it can be difficult glaucoma to manage.

And we don’t need to just manage the glaucoma. There’s all the other effects that go with it like the squint, the lazy eye, the high refractive error with spectacles, the patching that we need to do.

And so this has got to be a multidisciplinary approach. And so in our paediatric glaucoma clinics, we have specialist nurses, optometrists, orthoptists, ophthalmologists, family support, who are very important. They deal with the link between the hospital and the outside world and education, schooling and statementing and that sort of thing.

But as is true with any type of glaucoma, early diagnosis is essential, because this is an irreversible process. So if the damage has happened, that cannot be reversed. So if we diagnose it early, we can then hopefully, with the treatments that we’ve got, stop it from progressing. And we do have improving surgical options available. So this is improving prognostic factors, and we hope that that will continue.

So that’s the end of my little talk on aniridia and glaucoma. There were a few questions submitted, which I’ll try and answer as well. And then perhaps, if there’s a little bit of time, I can open the floor for you to ask any other questions really, hopefully related to glaucoma.

But one question was how does vision with aniridia typically change through childhood and then adulthood?

Well, this is a difficult question because every individual is individual and how they progress can be different from child to adulthood. Some people with aniridia have glaucoma and that can be well treated, and they don’t develop any other condition like the cataract and the corneal problem.

I always find the most difficult is the corneal changes, because actually it makes the surgery for the cornea much more challenging and increase graft rejections I mentioned earlier on. But glaucoma is a progressive disease, and so if that does progress from childhood to adulthood, there is a risk that vision can deteriorate along with the addition of all the other clinical factors associated with aniridia.

And that follows very nicely to the next question in the use of preventative eye drops for lubrication.

And I think this is very important, because I think if children and adults with aniridia lubricate the eyes and keep the surface of the eye nice and moist, that enhances the health of the cornea and tries to limit the extent of the corneal changes that can be such a problem later on in life.

There’s another question, does glaucoma differ in PAX6 related aniridia compared with other genetic forms?

Well, PAX6 is the major genetic mutation that causes aniridia. And in actual fact, I deal with a lot of other genetic conditions that develop into glaucoma. And really, whatever the underlying genetic mutation, the treatment’s very much on similar principles – medication, laser treatment, surgery.

Interesting work that’s going on at the moment is trying to correlate genotype with phenotype, meaning that if we know what genetic mutations cause the glaucoma, how does that affect how it affects the patient?

For example, if you have a particular genetic mutation, it may be that that causes a more aggressive type of glaucoma. So you may go for surgery at an earlier stage than if you had a mutation which is known to cause less severe types of glaucoma.

And so this is why genetics is becoming increasingly important. And a lot of the cases of childhood glaucoma, not just aniridia, is now we’re sending them off to Professor Moosajee and taking their DNA, so over time we can have a database that can help in this genotype-phenotype correlation, and then hopefully long term correct these mutations.

How does expertise in aniridia vary across the UK and away from large cities?

Aniridic glaucoma is obviously best dealt with in hospitals which deal with paediatric glaucoma. And these are actually very few and far between. Manchester has a very good department, as does Birmingham and in London at Moorfields and Great Ormond Street.

I think it’s important to be dealt with in a multidisciplinary environment if possible. But I think in general, if glaucoma needs treating as a secondary to aniridia, then you’re better off in one of these more specialised centres who are used to dealing with and operating on people with aniridia if the glaucoma develops.

So thanks very much for your attention and please, I’m happy to answer any other questions that you have.

[James] Wonderful, thank you, John. Very, very interesting. Yeah, we’ve had a few more questions and things come in. Katie.

[Katie] We’ve got a question from Emily. She says “My daughter uses Timolol. Will she definitely have glaucoma or can her IOP just be raised, and they are trying to reduce it?”

[John] Yes, that’s a very good question. If you have an elevated intraocular pressure, that does not necessarily mean you have glaucoma. You have to have nerve damage to be diagnosed with glaucoma.

Now, if somebody with aniridia is being monitored because of the aniridia and they’re being monitored for their visual development or their squint or whatever, and the intraocular pressure is being monitored and it starts to increase, the eye pressure increases before the nerve damage happens.

So if the treatment is started at the point where the pressure has started to increase but not yet damaged the nerve, then that’s not glaucoma. If somebody has a high pressure, that would almost invariably with aniridia lead to glaucoma if it was not treated early on.

So the fact that she’s taking Timolol does not mean that she has glaucoma, but she’d be at high risk if she wasn’t taking Timolol and the pressure remained high. Does that make sense?

[Katie] Yeah, I think so. So maybe a follow-up question then would be for anybody with aniridia who is just being seen because they have aniridia, how often should they get their eye pressure checked?

[John] So in general, while vision’s developing, so this is the 0-7 years of age, they probably need to be seen four-monthly for their vision development, for their glasses check, their patching, that their vision’s optimised.

After that, probably every six months, and as they get older, maybe less frequently. And there may be a point where then the optician can check pressures, so they’re not coming to the hospital all the time. But the younger the child is, the more frequent they need to be checked.

[Katie] So would they actually be having their pressure checked at each of those four-monthly visits?

[John] I think it should be checked at each of those visits, yes, because it’s so closely linked with glaucoma and because the treatment’s best picked up at an early stage. If they’re in the hospital having their vision checked in an ophthalmology department, then they should be having their pressure checked.

[Katie] And if someone was in that position of being able to be checked by the optician, how often should they do that?

[John] So these would normally be older people, older children and adults, I suppose I’d like to say annually, but probably six to twelve-monthly.

[Katie] Okay, so we’ve got another question from Andy here. “Have Moorfields considered doing clinics for people with aniridia with cornea, glaucoma and other specialists there to provide rounded care all in one visit?” We understand that the RVI in Newcastle are doing something like this and patients seem to like them?

[John] I got that question by email earlier and I’ve been thinking about it. I actually googled the RVI in Newcastle and I couldn’t find that they had a specific aniridia clinic. I could be wrong, but I couldn’t find it.

[Katie] We have had feedback from some of our members that go there that it is described as an aniridia clinic, or at least an all-round clinic for the multiple symptoms that can go along with aniridia.

[John] Yeah. I mean, it is in principle a good option, because when you’re dealing with rare conditions, often patients have to travel a long way, and so you don’t want to be travelling several times to different clinics.

So in principle, that’s a good idea. In practice, it’s a little bit more problematic, because very often now clinicians are working not just in one hospital, but in different hospitals. The volume outside the main centre of people with aniridia is quite low to set up particular clinics.

Although it’s not impossible and it doesn’t have to be a weekly clinic. It could be a monthly clinic or a two-monthly clinic and so on. But we’re also competing with other syndromes. A month ago, I was giving a talk at the Sturge-Weber weekend for parents and the same questions come up.

And so from a clinician point of view, it would be difficult to set up clinics in each different type of glaucoma. That’s part of where a multidisciplinary team is needed. So it’s something that I’m really seriously going to think about, but does have some logistical challenges to it.

[Katie] Okay, so we’ve got another question from Elena. So she’s asking “Regarding a viscocanalostomy in children, is it gentle? Or is there a better option? And also, what is the best implant for aniridia patients?”

[John] So a viscocanalostomy is a surgical procedure whereby a viscoelastic material, this is like a jelly consistency, is injected into the canal to dilate the canal, so more fluid can drain out of the eye.

So it is a relatively gentle procedure. And this comes under the angle procedures. So this is affecting how much fluid is draining out of the eye. And so this would be a useful procedure as a first line surgical treatment.

Now, there are other types of angle procedures, and it depends a little bit on the preference of the surgeon. So my preference would not be a viscocanalostomy, it would be a trabeculotomy. Now, you’re doing fairly similar things, just from a different approach, but both of these operations are perfectly acceptable and are quite gentle in their level of invasiveness.

And the second question regarding implants, is the questioner talking about implants after cataract surgery or implants to implant an artificial iris?

[Katie] Well, it could be talking about things like glaucoma tube, the tubes for tube implants. I’ve got a separate question in a moment about the iris implants. So if we assume it’s about glaucoma tubes, which one’s the best one for people with aniridia?

[John] Okay, so not to sound too complicated, but there are two types of tube. One tube has a valve, and that limits how much flow can drain down the tube. They very often fail. So if you’ve heard of an Ahmed valve, we no longer use what we call an Ahmed valve anymore as a tube implant.

The two most common ones nowadays are a Baerveldt tube and a Paul tube. Now my preference, and obviously if it’s my preference I think it’s the best one, is the Paul tube.

The reason being is that with a Baerveldt tube, because the tube is bigger, you have to completely block the tube off with a stitch, which takes up to six weeks for that stitch to dissolve. So you’re left with a high pressure after the surgery for at least six weeks. And further damage could happen while you’re waiting for the stitch to dissolve.

The Paul tube, the lumen is smaller. So you don’t have to block that tube off to prevent the pressure dropping too low. So when you do the operation, the pressure drops almost immediately within a day or two. So you get what you need to get straight away rather than having to wait. So the Paul tube is one that we would favour at Moorfields now.

[Katie] Okay. So yeah, there’s a question about iris implants. So you mentioned that we don’t do them anymore. So was that referring to Moorfields specifically, or would you say ophthalmologists in general in the UK?

And also, there’s mention of the Boston KPro, which I know is not an artificial iris, it’s an artificial cornea, which is something different. But that’s quite popular in the US.

Another thing that’s also quite popular in the US is a type of iris implant, a more modern one than some of the ones that I’ve heard about in the past. So the ones that are made by a company called HumanOptics, and they can be rolled up to be inserted inside the bag, which contains the lens. Or when someone’s having a cataract removed, it can be added in with the artificial lens you put in.

So just your statement about we don’t think that doing iris implants is a good idea. Does that also apply to that newer style of iris implants as well?

[John] Yes. I’m looking at this as a purely glaucoma specialist. And so when we when you get to my clinic and dealing with glaucoma, you really want to try and do everything to reduce the risk of making the glaucoma worse. And certainly the older style of artificial implants did have a much higher risk of not only making the glaucoma worse. But even if children didn’t have it, there was a higher risk of them developing it afterwards.

I have seen the ones that you roll up. I’ve got no experience of it, I’m afraid. In general, we tend to be able to manage the symptoms and I tend to try and avoid carrying out any other unnecessary surgery if possible, because the glaucoma is difficult enough to treat anyway.

Now, I know nobody at Moorfields does any of these artificial implants, either the older ones or the rolled up one. I can’t speak for anybody else. When we get together in… you know, it’s a small world, paediatric glaucoma… these things are not talked about. It’s just something that’s not very frequently done. I’d have to go back and look at the evidence for these other types of implants.

But in general, with the patients I see in my clinic who have glaucoma, I would tend to avoid any extra implantation, I would say. That’s not saying that they don’t have a good role elsewhere or by other people. So it’s worthwhile looking around if that’s something that people want to look into. And I’ll certainly look at the evidence once we’ve finished here.

[Katie] I mean, possibly also related to that is if somebody has cataract surgery, does that increase the risk of developing glaucoma?

[John] It does, I’m afraid, yes. So cataract surgery is actually the most common cause of secondary glaucoma in children. So when I put those on the slide where there were the most common types of glaucoma and the ones that need surgery, aphakic glaucoma is children who’ve had their cataract removed. And the younger that the child is when they have the cataract removed, the higher the risk there is of glaucoma.

So even in children, if they have congenital cataracts, not linked with aniridia or any other associated medical condition, and that is operated on, which it often needs to be, the earlier that they have the surgery, the more risk there is of glaucoma. And that will be true of aniridia as well. So if a cataract needed to be removed, that would increase the risk of glaucoma in children with aniridia.

[Katie] Okay, I think that’s all the questions that we’ve got.

[James] Yep, we’ve not got anything else. So thank you very much for your time John, much appreciated.

[John] Pleasure. Thank you very much.

[James] And we’re looking forward to getting your assistance with other enquiries that may come in, in coming months.

So yeah, just a general advert for the Aniridia Network Enquiries service. You can write into us at enquiries@aniridia.org.uk. We, Katie in particular, we’ll look at those initially. If we can answer them from the information we have to hand already, we will do so. If we need input from someone like John and Mariya Moosajee, then we will pass it on to them and get a real expert answer for you. So if you do have any questions, at any point, do get in touch with us, and we will do our very best to help you out.

So yeah, thank you very much John for your time, much appreciated. And thank you very much to all of our speakers today for their time and their expertise and their insights and inspiration. Really, really grateful for that. I certainly found it really interesting to hear from them all.

This event has been online, of course we are keen to do a physical event again. That requires volunteers. So if you would like to see a physical event happen, and if you would like it to be anywhere near you, step forward and help to organise it.

Yeah, that’s about it. So thanks very much for your time and can I be the first to say Happy Christmas! Bye bye, take care.

Posted in Medical staff talking | Tagged , , , , , | 1 Comment

Can access to station information improve train travel for people with sight loss?

Emily Nash

Talk by Emily Nash, Coventry University, at Conference 2025

Emily Nash is currently completing a PhD in improving access to train travel for people with sight loss. Her research is looking to identify and understand what barriers currently exist, and find solutions to overcome them. In this talk, she explains how interviews and a usability study are helping achieve this.

Emily lives in South Wales with her two children and they all have aniridia. She has been a member of Aniridia Network since 2015 and was a Trustee when she first joined. She also gave a presentation at the 2023 conference about her lived experience and the plans for her research.

Emily Nash on LinkedIn

Transcript

[James] Let’s move on now. We’ve got another presentation from another person with aniridia. I’d like to welcome Emily Nash to talk about train station maps for visually impaired people.

[Emily] Okay great, yeah. So I’m just going to talk now for the next 10 minutes just about the work that I’m doing, currently as a PhD student at Coventry University, in research supported by the Motability Foundation in Coventry University, looking at accessibility on our public transport and in particular on rail travel.

So the picture here is just of Paddington station. There’s a lovely little picture of Paddington just on Platform 1 there.

So just the overview of my presentation. I’ll give a bit of an introduction to myself. I will just talk about my PhD focus and a bit of a whistle-stop tour of some of my results. I’ll then just talk a bit wider, just what’s happening really in terms of accessibility on public transport, because it’s definitely a topic that is certainly being highlighted and discussed in Westminster. So we’ll just touch on that and then where I hope things will be going really.

Just as a bit of an introduction to myself. I know I definitely know some people on this call, but for anyone who doesn’t know me, I do have aniridia. I also have two children, who are in this picture as well, who are 8 and 11, who also have aniridia. And I also have my golden Labrador guide dog Kelly, who’s just sitting in between us on a train.

So I think my interest really in the area of transport has just stemmed from all of us really, just having that reliance, and we know it’s that connecting bit really to allow us to… whether it’s get to healthcare, school, education or social events really, that us being actually being able to use public transport is a real must really. But people’s experiences so far are just quite varied really, in terms of positive and negative experiences.

So in terms of what I’m doing, I am just coming to the end of my third year now as a postgraduate researcher. As I explained there, the support for the PhD has come from the Motability Foundation, who is doing quite a bit of work in this space, looking at accessibility for the wide variety of disabled people, and again all types of transport. So everything from walking and cycling, all the way through to our more structured networks of buses and trains.

What I was really hoping to do I think is two things really, just trying to establish the current experiences and that’s throughout the UK. So there’s been some smaller projects done either in London or Scotland, but really understanding common experiences in the current world, particularly post-Covid, as our transport systems are just becoming busier and more stretched.

And then looking really at how we can support people with visual impairment to just be more independent in their travel. So I know there are things like Passenger Assist, but I think there’s a real desire for people to be doing as much as they can themselves, which then gives them the flexibility really to travel as and when we want, rather than rely on a booked service that, as we know, has challenges as well in terms of its reliability.

So I’ve completed two interview studies, one with people with a visual impairment, across a variety of ages and locations and types of sight loss. So I interviewed 29 participants, about 18 months ago now. Following that I then spoke to professionals working in the area, so people working in charities or social services or in the rail operators, who really understand how individuals with sight loss are just being supported within the public transport area really, and making journeys independently.

And I’ve just come to the end of a usability study now, just looking at different types of station maps and information, and how people with visual impairment use those, and how they may actually assist us in travel and when we’re arriving at stations, and particularly those routes or those areas which are unfamiliar or changing for people. So this is a bit of a whistle-stop tour of some of the results I found, so sorry it’s a bit brief.

From the interview studies, and some of these bits won’t come really as a great surprise, there is a need just to understand the spectrum of visual impairment, and the different complexities that people struggle with really. So for some people, judging that gap is the difficult bit, for other people it’s seeing the signage, for other people it’s dealing with the crowds and the busyness really. So just understanding all the different complexities.

I think it would be nice if the simple answer was to have that consistency, and certainly there are moves to try and standardise what’s being done in the rail industry. You’ve got the Great British Railways being created, which will hopefully begin to assist with that. Because I think one of the challenges is definitely as you move across the country and you change between rail operators, they all manage and do things quite separately, and I think that’s exaggerated in the support they provide disabled people.

And then also just really understanding what support people with visual impairment want within a transport setting. I think of all the people I spoke to – and that’s on both sides, that’s both patients and those working with people with sight loss – real acknowledgement that quite often support, maybe around like white cane skills or a specific part of technology, but actually putting that together within the complex environment of station hubs and bus travel, you’re quite lucky if you receive that kind of support really.

So it does exist and there are some really good examples. But it’s certainly not consistently being delivered to people, which is really limiting their confidence really, and their belief and independence to do that.

So, as I said, the recent usability study I looked at was looking at maps that are actually available on rail operators’ websites. So when people look for station information, they tend to go to National Rail Enquiries, where there are just 2D maps, so a little bit similar.

So there’s two pictures on this slide. One on the right hand side, which is a 2D representation of a map, a little bit similar to what you might see on National Rail Enquiries. On the left is a much more interactive platform, where you actually see the front of the station, what it looks like, you can actually walk through the station, you can see what the ticket office looks like, you can see what the platforms look like. And there’s also actually a guided route planner which if you put in there that you want to go to platform 2, it takes you through the station and the route you need to follow, and where the lift is and where the stairs take you down.

Unfortunately these maps have been developed but are quite often buried in train operators’ websites. So of my 28 participants, no one actually knew they existed or where to find them. But there is definitely acknowledgement that having some idea of what a station could look like, of a route that might be needed within a station, would definitely be a benefit before travelling, and help some of that anxiety and planning and access to information.

So my study just looked at how easy it was to use some of these platforms, particularly with things like Voiceover, but also what information was actually critical to help people. I think it’s quite easy to add things, and there was certainly another site where there was a lot of visual information – it told you where all the trees were, but actually it’s not really important where the trees are. You actually just want to know where the signs might be or where the barriers might be, and so it’s just getting the right type of information.

So just to let people know, I don’t know how much people are aware that also at Coventry University there’s the National Centre for Accessible Transport, which is a group that’s been set up and funded by the Motability Foundation to look at a wide variety of issues within transport. So I was lucky to join when this was just starting.

So two years on, this is a bit of an outdated picture of us all actually at NCAT, but it’s the only one with me in really. But it very much came from the research that had been done, showing that experiences of disabled people, that there was a big gap, with disabled people making significantly less journeys than those non-disabled counterparts, and this really isn’t changing.

So there is definitely movement now to understand the different challenges and the different potential solutions that could help, and as I said earlier really, just in the complex area and actually the complexity of the support that’s required for us in order to do wayfinding and learn routes within this area.

So for anybody who’s not particularly familiar with NCAT, just to let you know some of the wider things that are happening, both in Coventry but wider really.

They do currently have funding applications open in order to address some of the issues and challenges that have been identified, which is great. And that’s smaller projects just to be initiated and actually trialled to see if solutions can help. It’s a lot more embedded in NCAT and they’re beginning to run these projects and publish their results. So they’ve just recently appointed a new CEO, which is just another step in its development really of NCAT.

Some other current things that they’re looking at is the complaint handling, because quite often a lot of the feedback was it doesn’t really feel as though the comments or the feedback are going anywhere. And quite often actually people don’t necessarily want to complain, it’s about that feedback loop and being part of the discussion really, being part of the table as to what could help and what would actually be of benefit to people.

As I said at the very beginning, there are discussions definitely in Westminster now around accessible transport, and Tanni Grey-Thompson’s been a big advocate for that.

And there is now an Accessible Transport Policy Commission, who have just issued a strategy document called Joined Up Policies and Joined Up Journeys, which has had a real focus really on the four nations – so Wales, Scotland and North Ireland and England – and really looking at individuals, where they are in those journeys of providing accessibility accommodations and support. and just providing a roadmap really for the next five years as to how they can do it in a collaborative way, but bring them all up to the same spec.

And then just for anybody who’s not aware, the NCAT panel does exist, so that people can get involved in research. You can sign up and they’ll send out requests for people to perhaps answer online surveys or get involved in focus groups. And that’s on the website, on the NCAT panel.

So just a little bit of summary really, this picture on this slide is just of me and my guide dog Kelly in Westminster Hall. So I was lucky enough to go for some training at Westminster at the beginning of the year, and be involved that I could provide submission when they were calling for ideas around joined up travel in the UK. So I was able to join up there.

So really for me the next steps are I need to write up my PhD, now that I’ve actually done it, so look out for that in the next six months. So hopefully I’ll be finishing that. It’s also allowed me to get involved now in the accessibility panel of Transport for Wales and the wider kinds of access for all transport in Wales, which is great. I’m going to an R&IB workshop next week as well, which is about future travel and what that might look like.

So I think the summary for me really is there’s quite a lot going on now in this space, and certainly NCAT and the NCAT panel is the place to go and find out more if you’d like to.

So my last slide is just some contact details for me if you’d like to know anything more about my research, or if I can point you in the direction, and look on the NCAT website. And I’m done.

[James] Thank you very much Emily, right on time. It’s wonderful to hear that someone like you, with Aniridia in particular, is involved in such important work as this.

One of the things that I encountered the other day, I was looking up at a digital destination board on a train platform, trying to see when the next train was coming. Unfortunately I was therefore looking upwards and the glass station roof was right above and the sun happened to be there as well. So although I could actually see the destination board, I couldn’t see anything because the sun was so bright shining behind it.

[Emily] So many examples. But yeah, one thing I probably didn’t really mention was to be selected actually to do the PhD, we all needed to have a lived experience of a disability.

And I think one of the big drivers of the research at the moment is that it’s being done and being conducted with people who have their lived experience, and that’s quite a big shift to get us all involved. And unfortunately it won’t really surprise people there’s obviously been quite a lot of challenges around that, and I could probably do another talk really on my challenges in terms of higher education and access in higher education.

But yeah, definitely a key bit really is that the users are involved and the people that have experience are involved in this research, and driving really what the solutions and answers are.

[James] Yeah, totally. So thanks very much Emily for that.

Posted in Other agencies | Tagged , , , | 1 Comment

Being A Carer

A arm in plaster holding a teddy bear on the chest of a woman wearing a hospital gown.

My mother and I both have aniridia.

My mother’s health significantly declined in 2025, as she struggled with the impacts of going blind, having falls and other effects of old age. And that in turn greatly increased my responsibilities as an unpaid carer for her. I’m documenting our journey in the hope that it raises awareness about:

  • Mum’s physical and mental health issues
  • the impact on me
  • the support we seek and receive.

Mum has talked to a fellow member of Aniridia Network through the befriending service. They were, lovely and had a lot of understanding about what she’s going through. It gave Mum some much-needed reassurance that everything she was experiencing was normal and she’s not alone. 

I also described my experiences on the RNIB Connect Radio Good Company programme.

Posted in Patients' tales | Tagged , , , | 1 Comment

The line running to and from Moorfields

By Sinead who has aniridia

Sinead and her sister in front of the Moorfields Eye Hospital sign
Sign at Old Street Underground Station. Large black on yellow text saying "Going to Moorfields Eye Hospital? Follow the green line on the floor

The other day, we travelled to Moorfields Eye Hospital in London to try to save the tiny bit of eyesight my sister has left. We were hoping beyond hope. 💛

When you get off the Tube at Old Street, there’s a green line painted on the ground that leads you all the way to Moorfields. It’s a simple but brilliant idea for people with limited vision – a clear marker guiding you from the station to the hospital.

I do appreciate that for those who are totally blind and travelling alone, it might not fully work. But for people with limited vision, it’s incredibly helpful.

Following that green line reminded me of the blue line in the Berlin Marathon I ran – except this time there was no finish line to sprint towards.

Painted green line on pavement

Instead, we were anxious about where this line would bring us:

  • to doctors
  • to decisions
  • to the unknown road ahead for my sister

We’ll be returning in the New Year, possibly for surgery.

If she goes ahead, the recovery will be long – 18 months to 2 years. The specialist treatment she needs isn’t available in Ireland, so her journey continues under the care of Moorfields. The financial road ahead is going to be very expensive.

The emotional strain over the past few months – and really the past few years – has been immense. Mostly for my sister, but also for me watching her go through it.

Losing eyesight can feel like a constant state of grief. Living with sight loss can be isolating and frightening.

The staff at Moorfields were absolutely wonderful, kind, and efficient. Their warmth made a very heavy day feel a little lighter.

And of course… my mandatory everyday run still had to be done. Even in London, I was out the door at 6am – routine keeps me grounded, especially on tough days. 🏃‍♀️💛

Please keep my sister in your thoughts as she faces the long road ahead. 💛👁️‍🗨️

Posted in Patients' tales | Tagged , | Leave a comment

Privilege, Protest, Power

Elliott at polling station

Talk by Elliott, person with aniridia at Conference 2025

“Identifying privilege, embracing protest and challenging power have all been integral to a journey these 25 years that I could not have imagined.

“Fighting for a seat at the table for the most marginalised has morphed into a passion, although that has only been possible through recognising my own vulnerabilities and taking part in civil resistance.

“Aniridia has shaped who I am, and I have driven that into a vision for a future that carries hope and dignity for all.”

Elliott is a social activist and political campaigner who champions the most vulnerable. From a shy kid to a vocal advocate, he fearlessly confronts hate, the political status quo, and even has an arrest under his belt (from protesting). His mission? To ensure every voice is given its place at the table.

In this talk, Elliott tells us more about his journey and campaigning.

Transcript

[James] Okay, welcome back. We are going to continue with our next presentation now, and I’m very pleased to have Elliott Lee with us.

I spotted Elliott’s various social media postings about all the wonderful things that he was getting up to in life, and knowing that he was a person who had aniridia I was very keen for him to come along and tell his story, and inspire everyone among our members. So over to you Elliott.

[Elliott] Thank you, and I should first apologise for anyone who can see my camera. It’s very dark in this room, and my blue hair blends into the blue wall behind me, so I probably look like a floating head for anyone who can see me.

But hello, my name is Elliott. In my day job I support victims of modern slavery and human trafficking, and just about every other waking hour I spend as a political activist and social justice campaigner.

Now the two different responses I get to that intro are usually either “Damn, he must be tired” or “Damn he’s pretty woke isn’t he?” The answer to both is yes, but this is the life I chose and ultimately this is the life I love.

Now, I want to tell you a bit more about my life, but first I would should say it’s a privilege to be here, although that privilege is not something I’ve always embraced.

For context, I was born in 2000 with aniridia. My development through childhood was not always the quickest. My speech and balance held me back. Emotionally I would get upset over the smallest things and would struggle to make friends at school. It was fair to say that I had my own vulnerabilities and was very much aware of them. If it wasn’t the constant shadowing at school, it was the all too regular doctor appointments.

In fact I remember at a young age, whilst playing with a Hot Wheels set, being told for the very first time that I would never be able to drive. I was probably too focused on the Hot Wheels set at the time. But a part of me started to understand that this was going to define me.

So what’s this got to do with privilege? Well, being able to build self-awareness of my vulnerabilities, similar to how as a child we could identify our strengths and weaknesses, I was able to make space for identifying my unearned advantages. Like, I could see that I was from a loving family, that I was from a safe area.

But a defining moment for me, where I had a better grasp of my privilege, I remember when I learnt of the 2016 Pulse nightclub shooting in Orlando, Florida. Now, despite having not come to terms with my sexuality yet and being so far away removed from the tragedy, I was angry, I was crying, I was upset.

But it so clearly lit a passion in me to take a fight to hate and inequality. I think we all have these moments in life, whether they be personal or external, that allow us to interrogate ourselves, to help us build on our character.

Recently, a moment I had like this was discovering I had a stem cell deficiency on my cornea. The experience allowed me to reflect on my vulnerabilities once again, see how my condition shaped me, and ultimately brought me back here feeling privileged.

It is what we do with privilege that is important. We know all too well how people exploit their privilege, but if we turn it on its head, well, we have protest.

Now don’t worry, I’m not about to encourage you to glue yourself to the roads. Only if you want to. That’s a joke, for legal purposes I’m sure.

For some people protest is different though. For some it’s holding up a sign, it could be wearing a pin, boycotting a certain brand. It could mean going to a rally expressing yourself differently. Being here today could be your protest, or for some people just existing is protest.

For me, the moment I could identify my passion in fighting hate and inequality, protest became a part of my journey. For me, protest has come in many forms – standing up to an unsupportive teacher, malicious compliance against a discriminatory employer and, more often than I like it, It comes in the form of writing a fierce complaint email demanding for improved services.

Protest is there for us to confront the status quo. It is there to give us a voice or a platform to those who otherwise could not speak up. It is part of our civil rights, which we could not have had without protest.

Now, don’t get me wrong, I love a good protest, if you couldn’t tell. In fact, I was arrested at one in 2023. Some may question why I risked this. So did my parents. In fact, when I told them about it, they weren’t impressed, I can tell you that.

But all I needed to do was look back on how I viewed my privilege, and at how my vulnerabilities have moulded my core values, which by name are non-negotiable in life. By laying these out, we have power. And power itself seems to be a common denominator here, between privilege and protest. While it allows me to have a punchy title for this speech, it’s clear this comes hand in hand.

Anecdotally I’m reminded of some elections that I’ve been a part of recently. At university, I was part of just about every campaign society you could imagine, not to mention running about half of them.

So when the Student Union elections came up, it was almost natural for me to stand as the anti-establishment candidate, with a campaign focused heavily around accessibility and accountability, both of which built on previous months of work on the issues.

So you can imagine my surprise when my opponents made the claim that accessibility wasn’t actually an issue and accessibility had been nixed. Shocking. A completely comical suggestion that was gaslighting every disabled student at university.

Immediately my campaign went from passive to offensive. Why? Because this statement was the complete antithesis of my values. By this point in my life I had experience in social care and the charity sector, and was studying international development. Advocating and bringing value to people’s lives was part and parcel of who I was. So I was not going to sit there and accept such dangerous language.

So how did I react? Every day, every event, every hustings, every conversation, sometimes twice, I would call them out. Yes, I became that protest candidate, but if that’s what it took, then so be it.

Now sadly, I did not win that election. But something interesting happened. Because the more I spoke up, the more conversations I had, the more backroom conversations I was having, by the end of the election nearly every other candidate had an accessibility point in their manifesto. And why was this? Yes, simply because I did not shut up about it. Now that’s what you call protest.

Now, I also stood in the general election last year. I got 3,107 votes. No, it wasn’t a small turnout, I didn’t win. You probably see a common factor here. But let me get to the point. Elections are very much a platform to speak truth to power.

In this campaign, I called out my local MP for going ahead with the two-child benefit cap, I challenged a private school for not investing in to SEND education, and I was able to talk confidently about my experience with the NHS when it got attacked. Yes, another election lost, but the power that came out of the privilege to stand was just as impactful.

So I want to leave you with a quote from a politician that I highly respect. Hard to find I know. So the quote goes: “If they find us so inspirational, then why don’t they put us at the table of power?” But I want to go one step further. We know we can be inspirational.”

So make noise, bang on the door if you need to, help others to the table, check your privilege, protest, and whether you take a seat or glue yourself to the tabletop, your voice deserves to be heard, because your voice is power. Thank you.

[James] Amazing Elliott, thank you very much. I think everyone will have got from that. I think I can hear a lot of the things that you’ve done there and some of the things I’ve done as well in speaking as an accessibility professional. It’s brilliant to hear your anecdote there about getting the other candidates to talk about the same issues. That’s a massive achievement, well done. Katie.

[Katie] Yeah, I was just gonna ask Elliott how much do you think specifically having aniridia has affected the work that you do? Obviously you’re passionate about a variety of different causes, but what do you think you could specifically link to having aniridia or a visual impairment, how that influenced the work that you do?

[Elliott] Yeah I would very much say that having aniridia, with my visual impairment, it’s almost ironically opened my eyes to the injustice that is experienced throughout. I guess it kind of started through SEND education, where I spent a lot of time as a kid obviously.

But that very much pushed me towards wanting to work within social care, the charity sector. So it very much pushed me towards working with people, and I think that’s how it started. And it escalated, and it’s got to the point where I spend every waking hour infused about activism and just wanting to see how I can best work with others to improve lives.

[Katie] Do you think having a disability, and the challenges that come along with that, then makes you more open to hearing the experiences of other people that are experiencing other challenges for different reasons, that perhaps don’t affect you personally?

Because I’ve found that, for me, I can see parallels between, say, disability discrimination and something like racism, or many different things. But just that idea of being in one group that’s facing discrimination or challenges makes you more open to hearing the experience of other groups?

[Elliott] Yeah, absolutely. It reminds me of the first time I experienced homophobia at school, or when I experienced misogyny against another student or racism. You’ll sit there and you’ll see that this person is experiencing the same kind of marginalisation that you’ve been experiencing yourself. So yeah, very much there is a good degree that I think people with disabilities are able to identify that.

Everybody has different lived experiences, and I talked about privilege there. I’m not always going to fully understand the lived experience of someone who is not white. I’m never gonna fully understand the lived experiences of someone who was born female at birth. But you’re very much set up to start to understand and identify when discrimination has occurred.

[James] Any other questions? Anyone want to stick their hand up and ask a question? Any comments? Anyone want to follow in Elliott’s footsteps and stand for election or make a difference?

[Elliott] Everyone should say yes.

[Anita] I was gonna say, yeah, it’s good to actually hear that people of your… I’m much older than you Elliott, but it’s good to hear that actually you’re so forward to do those things and create a voice, not only for you but for other people.

Because it can take a lot of courage and confidence for people to put themselves out there, because they get worried about what other people will think and how they might be judged. And so it’s good that you’ve been able to do that and you’ve had that confidence and that ability and that willpower and that want to do that. And it is very inspiring to see that young people are doing that.

Because, like you, I’ve stood, I’ve been a councillor in my local area. and I’ve stood in parliamentary elections and assembly elections and things like that. And I learned a lot from that. And it is something that once you start doing those kind of things and you’ve got the right support network around you, it isn’t actually as daunting as it feels. So well done on you for doing that

[Elliott] Thank you, and thank you as well for standing yourself. And I think although I very much talk about power in the sense of standing for elections, power comes in many different forms and there’s many different ways we can use it in life. So you can be powerful in your workplace, you can be an influence over a charity if you become a trustee.

There’s many different ways you can use your power in life, other than standing in elections. Just talking up, speaking up about your experiences is, like, all we know is just so powerful.

[James] Super, thank you very much. So we’ve also started doing some work with Elliott. We are working on a safeguarding policy for an Aridia network at the moment, one of the things that Elliott is hopefully going to help us with, which will just put us on a more surer legal footing and also just benefit the way that we handle interactions. things like at conferences and these kind of events, and social media and things like that. Make sure that we’re looking out for people, and treating people as they should, and dealing with any incidents that might arise properly.

So yeah, looking forward to working with you on that and other things Elliott. Thank you very much.

Posted in Patients' tales | Tagged , , , , | 1 Comment

Grow your skills, meet new people and help the aniridia community

3 young women with aniridia sitting at desk listen to a presenter

Are you or someone you know:

  • affected by aniridia?
  • keen to work better with people to achieve success?
  • willing to help enhance the lives of people affected by aniridia?

If ‘Yes’: Come to Bulgaria in April 2026 for the ‘European Aniridia Leadership and Collaboration Academy‘.

We’re seeking people with and without aniridia to join a 3-day event aiming to raise your:

  • self-confidence
  • interpersonal skills
  • ability to organise people and projects
  • knowledge of aniridia. 

Practical workshops and inspiring leaders will guide you through developing ideas to benefit you and the aniridia community, in the UK and across Europe. You will build connections with a range of professionals from around the world, many of whom have aniridia.    

Aniridia Network will pay the expenses of attending for a number of successful applicants

Find out more and fill in the quick Expression of Interest form NOW – even if you are unsure.

Then write a statement about how the academy will benefit you and the aniridia community (you will get more guidance after expressing interest). Submit it by 31 Deeember 2025.

Please encourage your relative with aniridia to sign up and do so yourself too!
You’ve nothing to lose and loads to gain as the previous participant Haya explains.

The European Aniridia Leadership and Collaboration Academy is organised by Aniridia Europe, the umbrella body of national aniridia associations such as Aniridia Network.

Posted in Aniridia Network news | Tagged , , | Leave a comment

Exploring PAX6 related gene regulatory networks & its role in the developing brain

Dr. Wai Kit Chan

Talk by Samuel Heczko & Dr. Wai Kit (Calvin) Chan, University of Edinburgh at Conference 2025

We all come from a single cell. But how does this cell know when and how to divide into a brain? And how does the aniridia-associated gene PAX6 guide this process? In this talk we learn about some fascinating research looking for answers to those questions.

Dr. Wai Kit (Calvin) Chan is a Research Fellow at the Centre for Discovery Brain Sciences. His research focuses on the molecular and cellular mechanisms underlying forebrain development and pathology, particularly in the context of human neurodevelopmental disorders. He is currently investigating PAX6 haploinsufficiency using advanced organoid and assembloid models, employing techniques such as single-cell RNA sequencing, immunofluorescence, and electrophysiology.

Samuel is a Phd student of developmental neuroscience under the supervision of Dr Chan. Samuel on LinkedIn.

Transcript

[James] I am delighted to introduce two people from the University of Edinburgh. As Mariya mentioned there, the PAX6 gene has a number of effects, and one of the ones that we don’t hear a lot about is the effect on the brain. And this is what Calvin Chan and Samuel Heczko have been looking into. So let’s hand over to them.

[Calvin] Okay, thank you for coming everyone. I’m Calvin. I’m going to talk about PAX6 and the brain.

So like Mariya said earlier, PAX6 does not only affect the eye, and one of the important organs that it also affects is the brain. So I’m going to talk a little bit more about that and what our research at Edinburgh Uni is, how we are looking into this problem.

So just a little bit of introduction here. PAX6 is an aniridia gene, but it’s also heavily involved in brain development. So if we take the brain, look at it straight forward, like just straight ahead, and we cut a slice right down the middle just to see how the brain is inside, we will see two bulges – one bulge at the top, which is the cerebral cortex, and at the bottom, which is the ganglionic eminence.

So these two bulges here are important because they give rise to the two types of neurons that we have in the brain, which are the excitatory neuron which gives excitation to the brain cells, and inhibitory neurons which curb, which dial down this excitation.

So what I’m showing here on the left is the expression of PAX6 in red. So you can see it’s expressed very highly in the cerebral cortex. That’s where most of our information processing is happening. But not very much in the ganglionic eminence which is at the bottom bulge.

So why this is important is because, like I said earlier, the cerebral cortex, or the top part of the bulge, where PAX6 is very highly expressed, gives rise to excitatory neurons, which are coloured here in green. And PAX6 is not expressed at the ganglionic eminence, which is the bottom bulge I’ve coloured here in pink, which gives rise to inhibitory neurons. So these inhibitory neurons are born in a different region of the brain, but they will need to move, migrate tangentially, up into the cerebral cortex to form cortical circuits.

So just to talk in a little bit more detail about what kind of symptoms that you see in the PAX6 patients. You have both copies of PAX6, so the full dose of PAX6. You see here on the left, this is an MRI scan of a control patient and you can see what I’m going to highlight here is the corpus callosum. It’s right in the middle of the picture, it’s highlighted by this white arrow.

Basically this is the largest axon track connecting the left and the right hemisphere of the brain. And in PAX6 patients we see that this connection, this axon track that we call corpus callosum, either they are very small or they are absent in the PAX6 heterozygous patients. So there are problems with inter-hemispheric connectivity.

Another brain phenotype, that brain symptom that we see, is also a decrease in cortical thickness. So the cerebral cortex, which I talked about earlier, is the top part of the brain. If we measure the thickness between control and patients, we see that this region of the brain is slightly thinner in the patients, and it’s not very region specific. It occurs throughout the whole brain that it is thinner.

So those are just a few examples, because we are short of time that I can give. So mainly what I’m trying to highlight here is there’s structural malformations in the brain if you lose one copy of PAX6.

And how do we study this in the lab here in Edinburgh Uni? So we use a model of human cerebral cortex. We use a model called the cerebral organoids. So how the cerebral organoids come to be is we have some human pluripotent stem cells. So this can be patient derived. We can take some samples of the patients, we can reprogram them into stem cells, then we can make them into these 3D tissue culture models that we call cerebral organoids.

So how does this work? From the stem cells we can aggregate about like 9,000 of these cells into little balls, what we call embryo bodies. And by changing differentiation medium in these embryo bodies, they will slowly develop to make neuroectoderm. These are the precursor cells to what you get in the brain. And if you let it develop, I think I can play this video here.

So this is how we culture it in our lab. So we culture it on a shaker. If we keep developing these embryo bodies, they will slowly expand their neuroepithelium. And all these cells will continue to develop into what we call cerebral tissue. So this tissue will contain all the cell types that you would find in a human brain. And because it’s a more accessible experimental system, we can go and look into these cells and what they are.

So how do we do that? How do we look into what type of cells that these organoids make? So we use something called single cell RNA sequencing. So to do this, we will now take out cerebral organoids and then we will dissociate them into single cells.

So after dissociating them into single cells, we will then do some RNA extraction to see what RNA is being expressed in each of these single cells. We can sequence all of these RNAs and then we can have an expression profile of each of these cells that we have in our organoids. And from this expression profile, we can tell what cell type is being produced, what cell type is not being produced.

And I’m going to talk about one of our results that we got from this study. So here I’m showing a graph of the single cell RNA sequencing readout. So if we lose both copies of PAX6, this is not a condition that you will see in human patients, because loss of both copies of PAX6 is lethal. But for an experimental setup, we wanted to see what is the role of PAX6 by just removing all of PAX6 altogether, to minimise the confounding effects here.

So I’m going to explain a little bit about the graphs here. So each dot here is a single cell and each dot is coloured with a cell type. So there are many cell types that we found in the brain, but I want to highlight just two of these cell types here, which coloured in blue is the excitatory neurons and coloured in red are the inhibitory neurons.

So if you look at the left here on the PAX6 control, we see that there are a lot of excitatory neurons that we find in our organoids. But if we remove PAX6, we still find some of these excitatory neurons, they are reduced. But we see this huge increase of inhibitory neurons being produced instead. So we think here that there’s a change of cell fate. Normally the cells would become excitatory neurons, but instead of becoming excitatory neurons, now if you lose PAX6, the cells are now becoming inhibitory neurons instead.

And why is this important? Because if you look at the cerebral organoids inside, so we can section these organoids and then do some immunofluorescence staining. So by staining, we can see how the cells are organised, so not just the identity of the cells by looking at RNA sequencing, we can also look at how the cells are organised in our organoids.

So here we did staining for the excitatory neurons and the inhibitory neurons. The excitatory neurons are coloured in green here and the inhibitory neurons are coloured in red, so these are the markers. So if you look at just the control organoids, we do not see this inhibitory neuron markers coming up, so there’s not that many of these inhibitory neurons. We only see clusters of excitatory neurons being born, so those are just in green.

But if we look at the PAX6 mutant, where we don’t have any copies of PAX6 at all, we see these inhibitory neurons being shown in clusters. But what is interesting to us is that these red clusters, or these red inhibitory neuron clusters, are segregated from the green excitatory neuron clusters. So I’m going to show a better section illustrating my point.

So if we analyse all these images that we got back, we see there are two different territories being produced here in the cerebral organoids. The green excitatory patch and then some red inhibitory patch of cells.

So this is not normal, because as I described to you earlier, although these inhibitory neurons are born in different places, they would migrate into the cerebral cortex, so they would intermingle with the excitatory neurons to form a cortical circuit. If this intermingling, or this migration, does not happen, then we will have some circuit dysfunction.

So what we are thinking that’s happening here, at least for the structural abnormalities we see in the patients, is that we have inhibitory neurons being produced when we lose PAX6. And these inhibitory neurons are probably going to be a little bit abnormal, but we need to do a little bit more analysis and more studies looking into this. Because they segregate from the excitatory neurons, this might affect the cortical circuit functions. But also, because of this extreme segregation, it is possibly causing these structural malformations that we see in the patients.

So that is all I have to say for now. This is just a summary. I’m going to hand on to my PhD student, Sam, who’s going to talk to you in a little bit more detail how we think these mechanisms give rise to these inhibitory neurons.

[Samuel] All right. Hello, everyone. Greetings from sunny and rainy Edinburgh. So my name is Sam. I’m Calvin’s PhD student, and I’ll be talking a little bit about how these abnormal cell types arise in the developing brain without the PAX6 gene. So, yeah, thank you so much for having me, I’m very excited.

So as Calvin explained earlier, we see a rise of these abnormal cell fates in the brains without the functioning PAX6 gene. And to really understand how do these cells, quote unquote, “decide” to take a cell fate which is abnormal, we really need to understand what a cell type is, because this is something that’s actually surprisingly complex.

So all of our cells contain exactly the same genome or a very, very similar genome. And all of our cells contain all the genes which code for all the important functions of a cell that the cell can have. And these different proteins that are coded by the cell give rise to the biological function of the cell, which we call a cell type.

For example, if you think about a skin cell, it needs to code for proteins which create this barrier around us, so that the outside world doesn’t hurt our organs. Or if you think about an eye, the cell has to code for proteins which are transparent so the light can travel through the eye, such that we are able to see.

So this happens despite the fact that all of our cells have all the genes. So somehow the cell has to decide which of these genes which are in the genome are transcribed and translated into proteins, so the cell gets its correct biological function. And this is exactly the same for the brain cells.

So the excitatory and inhibitory neurons code for a slightly different set of proteins which is altered in the mutation of PAX6. So what we are really trying to see here is how does the cell decide to code for these proteins, and how does the decision to which proteins to code for depend on the gene PAX6.

So the way that the genes are coded is through transcription and translation. And transcription is regulated through something called cis-regulation. So this is a picture of the DNA molecule, a little cartoon of a DNA molecule, which all of us have in all of our cells. And this DNA molecule contains genes. The gene could be for example here, which is marked with an RNA on this little plot.

There are also other regions in the genome which don’t code for specific genes. So these genes are recipes for the proteins which then create the biological function of the cell. However. not all the regions in the DNA code for genes, and the other regions in the DNA which regulate the amount of genes being transcribed, which then gives rise to the cell type which we observe.

So these regions are called promoter and enhancer regions, and these promoter and enhancer regions have special chemical properties which allows them to bind transcription factors. And transcription factors are special proteins which bond to DNA, and when they bond to DNA they have target genes which are expressed more or less depending on the biological function of these promoter and enhancer regions in the genome.

So what is important here and what it has to do with my data is that these promoter and enhancer regions to bound transcription factors, and therefore to suppress or enhance gene expression, have to be available. And this availability is determined by the fact that the DNA in general has 3 billion base pairs, so it’s a very very long molecule and most of it is wrapped around histones like we see here on the right hand side of this plot. However, for a gene or enhancer or promoter region to be active, to be available for a transcription factor to bind into it, it needs to be unwrapped, so it needs to be genetically available.

And this is the data I’m working with. So my data contains availability information from each cell, and I have cells which have PAX6 and which don’t have PAX6, just like Calvin explained earlier. And I’m looking into if we can see differences in the availability of these regions.

Because if we see that the regions are differentially available in between cells which have PAX6 and don’t have PAX6, that could mean that transcription factors bind differently to them, which effectively means that they code for a different set of proteins, which could give rise to these new abnormal cell types which we observe in our system.

So this is a very new direction of research and we don’t have any concrete answers as of now. However my preliminary data shows this. This is my data I decided to share with you guys today. And this is a UMAP and this is the same plot that Calvin showed you earlier.

So each dot on this UMAP represents one cell in our data set. And the dots are split in a way that the distance between each of these dots corresponds to the similarity of these cells, and the similarity is from the regions being similarly available. So dots which are close to each other have a very similar availability profile, however dots which are far away from each other have a very different availability profile from each other.

Each of these dots is colour-coded into the blue dots which have PAX6 and orange cells which don’t have any PAX6, and the cells develop from left to right. So on the left hand side we have progenitor cells and on the right hand side we have mature neurons to which these progenitor cells develop into.

So what’s important here is. just like in the data that Calvin showed us, cells without PAX6, if we look at the right hand side we can see that they form very normal neurons. So this we can see from the fact that the yellow and the blue dots are very close to each other. So these cells are very, very similar to each other, which means that the cells without PAX6 are essentially the same as the cells without PAX6, and this is what happens in the mature neurons and these had excitatory neurons that Calvin talked about earlier.

However, if we look on the left hand side of this diagram we see a very different story. So in this left hand side diagram the cells without PAX6 and with PAX6 separate quite distinctively so that means that without PAX6 you get a very different availability profile as compared to the cells which have functioning PAX6.

So what we see is in the early development the cells are quite different. However, the cells without PAX6 are able to develop into very normal neurons, but what also happens is we get this arrival of this abnormal cell type, which we can see here on the bottom, this orange little arm here.

So we see that some cells don’t develop into the correct direction and they develop into this sort of dead-end developmental track. So that is not good, that is not healthy. However, we know that this mechanism can be modelled through the availability of DNA.

And what is new here is that it looks like PAX6 changes the availability of a cell. Not only PAX6 binds to DNA itself to promote genes or suppress other genes, but also makes the genome less or more differently available, so that other transcription factors might have a bigger effect on our cell development.

So right now what I’m doing is I’m looking into how to possibly manipulate and quantify these availability changes in such a way that we could encourage these cells without PAX6 to develop into the healthy development, which is clearly possible as we see from our data, and to minimise the amount of cells that develop into these inhibitory neurons.

So to conclude, the transcription factors they bind only to available regions, and PAX6 changes the DNA binding dynamics of many transcription factors, because PAX6 changes the availability profile of the genome in a very global way, and this could be a plausible mechanism for the change in the cell fate which we observe. However, this still needs to be properly quantified. And I think next we will investigate what happens when only half of the PAX6 is present, which is the condition which is clinically relevant.

So that concludes my talk, thank you so much for listening. I’m very happy to answer any questions.

[James] Thank you very much Calvin and Sam, absolutely fascinating, yeah, absolutely. We’ve not had any questions come into the chat, so one quick one please. When we first got in touch with you, we discussed about you having some engagement with the patient community, which is brilliant that you’re here today. I just wondered if there was anything that Aniridia Network and our members can do, either with your particular research, follow-on research or anything like that.

[Calvin] Yeah, so at least for me, I think it’s good. I would like to have more engagement with the patients and talk about their… I mean, other than the eye symptoms. if we can understand a little bit more about the symptoms that they’re experiencing that are non-eye related, so very relevant to what Mariya is looking at. But obviously we want to focus a little bit more on the brain side of things, which is maybe some behavioural phenotypes, some sleep disturbance and issues like that.

[James] Marvellous, okay thank you very much for your time once again, really appreciate it, and hope to hear more results from you as your study progresses.

[Calvin] Yeah, thank you very much.

[James] Thank you.

Posted in Research | Tagged , , , , , | 1 Comment

How PAX6 gene deficiency affects your body

Talk by Professor Moosajee, Moorfields Eye Hospital at Conference 2025

Woman wearing a white coats in a laboratory
Dr Mariya Moosajee

It is now accepted that reduced PAX6, caused by genetic changes involving the gene, does not just affect the eye (causing aniridia) but has an impact on many other organs of the body.

In this talk, Professor Mariya Moosajee explains the impact of PAX6 outside the eye, and expands on insights gained from looking at all the metabolites in the blood of aniridia patients.

Professor Mariya Moosajee is a clinician scientist, she is a Consultant Ophthalmologist specialising in Genetic Eye Disease and Head of the Genetics Service at Moorfields Eye Hospital, Professor of Molecular Ophthalmology at UCL Institute of Ophthalmology, and Group Leader of Ocular Genomics and Therapeutics at the Francis Crick Institute, London.

@MariyaMoosajee on Threads
@profmariya on Blue Sky

Transcript

[James] Right, I’m going to pause my screen sharing and hand over to Professor Mariya Moosajee for our first talk. Welcome Mariya.

Mariya has recently been appointed as our medical advisor and we’re delighted that she’s here today, along with John Brookes a little bit later, to give us the benefit of their knowledge. So over to you Mariya.

[Mariya] Thanks James. Hi everyone, so nice to see so many of you, and really nice to actually read everyone’s little bios in the chat.

So it’s my pleasure for the next 20 minutes just to talk about the role of PAX6 and how it affects the rest of your body outside of the eye.

A little bit about myself, I am a consultant ophthalmologist, I specialise in genetic eye disease, and I see children and adults at Moorfields Eye Hospital. And I have a long-standing clinical and research interest in aniridia, and so I have seen a lot of patients with this and continue to do so.

I work with a fantastic team. One of the consultants, a neurodevelopmental paediatrician works with me, Ngozi Oluonye, she’s also on this call today. But you can see there’s a picture of the wonderful team that work to look after our genetic patients.

And then I’m also a professor of molecular ophthalmology, a scientist, and I work at UCL Institute of Ophthalmology and the Francis Crick Institute. And again I have a wonderful research team, who over the past few years have done some great research into furthering our understanding of aniridia.

So when we think about aniridia, especially as eye doctors, we tend to consider it mainly as an eye disease. And it’s an eye disease that we know can affect many parts of the eye.

So the most obvious feature is that you get complete or partial loss of the iris, leading to having a large black pupil. Children often will present with nystagmus, the involuntary movement of their eyes, which can be apparent from six weeks of age.

Individuals will suffer from reduced vision and this is partly because an area of the back of the eye called the fovea – your area of central vision – hasn’t developed fully in aniridia, and we can detect this by doing various scans in clinic.

But individuals can also have abnormalities involving their optic nerve, the nerve that sends signals from the back of the eye to the brain. It can be underdeveloped or it can fail to fuse completely, called a coloboma.

Later on, individuals can develop cataracts, glaucoma, corneal keratopathy leading to opacification of the cornea, you can get droopy eyelids, and some patients can even get retinal detachments.

But aniridia is no longer considered an isolated eye condition. It’s thought now to be a syndrome that affects many other parts of the body, and certainly in the last Aniridia Europe meeting there was a big discussion to maybe change the name of Aniridia to PAX6 Aniridia Syndrome, so it reflects more correctly the involvement of the rest of the body.

So there are various different features that affect different parts of the body in aniridia patients. Individuals can suffer from obesity, they can suffer from diabetes and, prior to a diagnosis of diabetes, insulin resistance and high glucose levels in the blood.

They can suffer from something called central auditory processing disorder. So their hearing is normal but their processing of what they’re hearing is not quite correct. And I’ve given a silly example, but if I said “grab the reindeer”, they may actually hear “grab the rain gear”, which is slightly different.

Patients can suffer from problems with their sense of smell. They can actually have partial or full loss of smell. They can have brain abnormalities, so the brain structure itself hasn’t developed properly. They can have sleep disturbances, and a lot of patients develop behavioural issues such as autism and attention deficit hyperactivity disorder. And some patients can develop depression and anxiety.

So the reason this happens is because PAX6 is not just involved in eye development. It’s working in other parts of the body, such as the development of your pancreas, and particularly the cells that produce insulin. And that’s why patients have a higher predisposition to endocrine problems such as diabetes.

It’s also involved in how the brain develops, hence the issues with the structure of the brain, the problems with the sense of smell, and potentially the behavioural issues.

And so having only half of the healthy PAX6 gene is the reason why we have these developmental issues, and why we get this secondary disease that occurs later in life. And just to highlight that, I’ve got a diagram here.

So we explain to patients that we inherit one set of genes from our father and one set of genes from our mother. So if we can imagine we have two copies of every gene – one from mum, one from dad. So we have two copies of the PAX6 gene.

Now, in my case, I have two healthy copies of the PAX6 gene, and it produces a full amount of PAX6 protein, and that allows my eyes to develop healthily.

But in aniridia, you inherit one healthy copy of the PAX6 gene from one parent, but you can inherit a bad copy of the PAX6 gene from a parent. Or you yourself, when you were developing in the womb, may develop a mutation on one copy of your PAX6 gene.

And that leaves patients with aniridia with one healthy copy and one bad copy. And because of that, you only have 50% of healthy PAX6 protein and 50% is missing And it’s that lack of that 50% that gives rise to all the problems.

So we undertook a study a few years ago, where we looked at all patients at Moorfields Eye Hospital that had a diagnosis of PAX6-related aniridia. They had genetic testing and they had PAX6 mutations. And we looked at some of the involvement of other body parts.

And what we found was that in our cohort we identified a large number of patients with type 2 diabetes. Around 13% of patients had this and this was actually twice the UK prevalence. So an aniridia patient is twice as likely to develop diabetes than someone in the normal population.

A large number of patients, over 23%, had obesity, 7% had learning difficulties and 2% had autism. And there were other associations with hyperthyroidism, hypertension, high cholesterol levels and also asthma in the cohort.

So we wanted to try to investigate this a little bit further, by trying to see if we could detect any changes in the blood of our aniridia patients, that could explain why they were more predisposed to these conditions affecting the rest of their body.

And so we decided to do something called whole metabolomic profiling. So essentially what this means is that you can take the blood of a patient, and you can spin the blood down, and you can extract the plasma from the blood. And then you can send this plasma and you can screen it for over a thousand metabolites in the blood. And this could be proteins, it could be carbohydrates, fats, vitamins, caffeine, any metabolite that’s in your bloodstream it can detect it.

So we did this for 25 aniridia patients and 25 age and gender matched healthy controls. We got every single patient to fill out a food frequency questionnaire and this gave us an idea of what individuals were eating over a period of time, to make sure that the results were not skewed – for example, aniridia patients having a much healthier diet than their normal controls or vice versa.

But we found that there were no differences in the dietary intake between aniridia patients and healthy controls. And we had to exclude patients that had diabetes, or those that were taking statins for high cholesterol, because that would have altered the blood metabolites.

So we included seven children in our cohort and 18 adults. The mean age was 31 years and 48% of the participants were male.

Now we calculated an individual’s BMI and then we grouped it, and we found that actually the aniridia group fell into the overweight category, whereas the control group fell into the normal healthy BMI category.

So that’s a difference in itself, showing that although your diets are the same, the aniridia group was still more overweight than their healthy counterparts. If we looked at the composition of people in the cohort, 44% of the patients actually had obesity, compared to only 16% of the controls. Some of the aniridia patients suffered from gastric reflux.

There was a balanced amount of patients with hypertension. There was a slightly increased number of patients with central auditory processing disorder in the aniridia group, as with depression, anxiety, learning difficulties, ADHD and autism. There was one patient that had pineal gland hyperplasia, and three patients that reported sleep disturbances and were on a melatonin supplement.

So when we ran this experiment we found that there were over 94 metabolites that were different in the aniridia group compared to the healthy group. And the five main groups that were different were lipid (or rather fat) metabolism, oxidative stress, complex lipids, neuroactive metabolites and microbiome-related metabolites. And I’m going to explain some of these in a little more detail, just to give you some further insights.

So fat metabolism was disrupted. We found that there were disrupted markers of something called our fatty acid metabolism in our aniridia patients, and particularly some metabolites called carnitines. And when we looked into the literature, we found that patients who have increased carnitines have been linked to diabetes and heart failure.

So that’s just something to bear in mind, that having high carnitines in your bloodstream can be linked to cardiovascular disease and diabetes.

We found that aniridia patients had reduced levels of something called plasmologens. Now, what are plasmologens? Plasmologens are a type of fat that are found in our cell membrane.

So our body is composed of billions of cells, and the outer protective layer of our cells is called a cell membrane, and it has lots of fats in it, and plasmologens are one of them.

So these plasmologens normally provide our cells with stability and fluidity. It allows them to move properly as they should and it also gives them the ability to protect them from something called oxidative stress.

So oxidative stress is something where when you have lots of chemical reactions going on within the cell, you can generate metabolic byproducts like charged oxygen molecules, and these can whizz around within your cell and cause damage.

And so our cells need to find a way to protect themselves from these charged oxygen molecules, and that’s called antioxidants. So we need antioxidants to counter oxidative stress. And when you have reduced plasmologens, you reduce your ability to provide an antioxidant protection.

And interestingly patients with other rare diseases, for example a condition called Zellweger syndrome where patients develop cataracts, also have low plasmologen levels. And so it could be that these low plasmologens may be predisposing our aniridia patients to cataracts.

We also know that patients who have diabetes and higher fat levels in their blood and cholesterol can also have reduced plasmologens. So again this is a very interesting biomarker that points towards aniridia patients having a predisposition again to diabetes and cardiovascular disease, and cataracts in this case.

We then found that ketone bodies were high in our aniridia patients, there was an accumulation of them. Now we tend to see high levels of ketone bodies in patients that have uncontrolled diabetes.

Now remember, our cohort did not include diabetic patients, none of them were taking any diabetic medications. And interestingly there were other markers linked to high ketone levels and ketones leading to our blood being more acidic. And so taken together this suggests that our aniridia patients are in a pre-diabetic stage, possibly in an insulin resistant stage.

And so that’s something that we need to think about in terms of making sure that our aniridia patients are referred to endocrinology, that they’re monitored either by their GPs or endocrinologists, potentially in case they are going to go on to develop some form of diabetes, and if they need to put dietary or drug treatments in place before they get to the point where they need to have, for example, insulin injections.

So we also found that oxidative stress was high in the blood of our aniridia patients. Now I explained to you what oxidative stress is and there are certain markers in our blood that indicate that.

So there is a compound called taurine and this is actually a natural antioxidant. And we found that taurine was reduced in our aniridia patients. And its precursor – so the chemical compound that makes taurine in our bodies – hypotaurine, was also reduced. And so you’ve got antioxidants reduced in our aniridia patients and oxidative stress markers increased in our aniridia patients.

So what can we do about that? Well taurine, the antioxidant, is really important in our bodies. It helps us to make our bile acids and it also stimulates insulin release. Now that’s important, because we know that the cells that produce insulin in aniridia patients are already not functioning very well.

So if you’ve got something that doesn’t help stimulate the insulin production, that’s going to have an even more knock-on effect on the predisposition to diabetes. So in other conditions such as depression, schizophrenia, autism spectrum, hypertension and obesity, patients are also found to have reduced taurine levels.

So one thing that we would like to now investigate in our lab is potentially giving our aniridia disease models taurine supplementation. Because if this shows that it’s a benefit, it may alleviate a lot of the problems that our aniridia patients are facing. So this is a body of work that we want to take on going forwards, but taurine supplementation may be something that really could help the aniridia community.

So neuroactive metabolites were also found to be slightly deranged in our aniridia patients. So particularly a component called N-acetylaspartate. This was found to be increased in our aniridia patients. And interestingly N-acetylaspartate is one of the most common what we call neurotransmitters in patients.

So when you have a nerve ending and a junction between nerves, and it wants to send signals between two nerves, one nerve has to release a neurotransmitter which passes across a junction, so the other nerve can detect it and then start to send the signal onwards.

And so when there are very high levels of this neurotransmitter, it has already been found to be associated with neurodegenerative disease, but also it’s being detected in the brain of female children that have been diagnosed with attention deficit hyperactivity disorder. So just something also that could explain some of the behavioural issues that we’re seeing in our aniridia patients.

So, just to summarise, PAX6 does not just affect the eye. It does have an influence on other systems outside of the eye – obesity, diabetes, brain function and structure, sleep, behavioural issues, depression and anxiety.

And by investigating the blood, and potentially having an even more closer look at the general health of aniridia patients, not just early on but in some of our patients that are later on in life, we might get some more insights into how PAX6 affects individuals throughout their lifespan.

So just a bit of general advice on what you can do to maintain good visual function and general health.

Well, it’s always important to have your regular follow-ups with your ophthalmologist. If you are experiencing any of, or some of, the features that I’ve mentioned today in the talk, but you’ve never seen anyone for it or raised it with your eye doctor or your GP or anyone else, then I would suggest that you go to your GP, ask for a referral to a specialist like an endocrine doctor. But also bring it up with your ophthalmologist and they can refer you directly to hospital specialists as well.

But please don’t be sitting in silence. Think about the features that may be affecting you that you may previously not have thought were linked to your aniridia in your eyes, but this might be enlightening for you.

Think about your diet. It’s always important to have lots of fresh fruit and vegetables. Green leafy vegetables are incredibly good for you – spinach, kale, broccoli, salad, anything green, they’re rich in antioxidants. And fresh fruit, and fruit specifically that is blue, black and red in colour – so strawberries, blueberries, blackberries, black and red grapes, pomegranate. Anything of those colours are very rich in antioxidants so you should have loads of those in your diet. Eating fish twice a week is incredibly good for you, it’s got omega oils in there. It’s important to take regular exercise

You guys all know that it’s important to wear your UV-protected tinted or dark sunglasses in bright light. Try to get yourselves blue light screen protectors on any devices you’re using, especially if you’re holding those phones or iPads very close to your eyes. It just prevents the blue harmful light from entering in, which can also affect your sleep as well.

And then make sure you’re getting all the support that you require. So if you haven’t been sight registered, when you next see your eye doctors just make sure you raise that as well, so that you can get all the support that you need.

For any of you on the call that want to participate in aniridia research. you can register with something called Research Opportunities at Moorfields, called ROAM.

Stay in touch with Aniridia Network. Anytime we need aniridia participants we always get in touch with James and the team and send out emails, so we’re always thankful to you guys for that.

And please help fundraise, because the more funds you can raise, it means the more work that we can do, and the more research we can do to advance our understanding and knowledge, and go on to develop treatments for our aniridia patients.

I draw your attention to Gene.vision, a website we created which is fully accessible to patients. It’s got a whole page on Aniridia / WAGR Syndrome, all in lay. It’s also got information on the latest research and any other information that you need to access relating to sight loss.

So to conclude, aniridia can affect many organs in addition to the eye. We need to make sure that you are looked after holistically and we get the correct specialists in place to optimise your care. Please do visit your GP or tell your specialists if you’re experiencing any systemic problems that require any further investigation or input.

If you want to get in touch with me, you’re always welcome. We welcome you to come visit our clinic, even just as a one stop to say hello and making sure that you’ve got everything that you need. My email address is m.moosajee@nhs.net.

And a big thank you to Aniridia Network, to my clinical team and my research team. Thank you so much.

[James] Thank you very much Mariya. We’ve got time for one very quick question, and others we will pass on to Mariya and get you responses to those later. Katie.

[Katie] Florian has asked about whether there were a correlation between the different symptoms. Say, could a sleep sleep disturbance in itself cause some of the other symptoms that you found in the patients, and is there any progress towards quantifying these symptoms more, and screening for them even?

[Mariya] Yeah, so we’ve actually conducted some more work. We still have to analyse all of that. But following on from this work… because that was just 25 patients, which is enough to make a comparison between healthy and aniridia patients, but actually what we need to do is actually reach out to many, many more aniridia patients and actually find out exactly are there any correlations.

But to answer, yes of course, if you have a sleep disturbance and you’re not sleeping well, that can lead to, for example, low mood. And if you start to suffer from depression, then you start to eat more, and then you can put on weight. And so there can be vicious cycles that go on.

But what we found was that actually when we took diet out of the question, there were still things going on and our metabolism was showing that it was different between the two groups. So PAX6 I think is the underlying cause.

However, of course there’s going to be confounding factors, depending on your mood, on your sleep, etc. So a lot more work needs to be done to tease those correlations out.

[James] Marvellous, thank you very much Mariya, much appreciated. As I say, we’ll pass on the other questions that have come into the chat onto you and will get those back to the relevant people.

[Mariya] No problem, thank you everyone, thanks.

Posted in Medical staff talking | Tagged , , , , , , , | 1 Comment

Conference 2025

“I found it very informative and took things from each of the talks that I feel like could use going forward to inform my own family and myself when dealing with our healthcare” Attendee

Our main event of the year was held online, 1-4pm on Saturday 1 November 2025. We had wodnerful speakers, to talk about a range of aniridia-related issues: from personal experiences to cutting-edge research.

We recorded each of the sessions and expect to publish them later on YouTube when a volunteer is able to.

37 people came along and to meet others with aniridia, and the fantastic medical and scientific experts pushing forward our knowledge on aniridia.

Trustee and communication volunteer James, who organised and ran the event said

It was another great conference for Aniridia Network. On behalf of all our members, many thanks to all the speakers for the time and effort they put into presenting to us, and for the work that led up to it too.    

James running an Aniridia Network online conference from his home office. He is using 2 monitors. The left is editing the main slide deck showing 'Conferences and Events' and the right has an in progress talk on Zoom

Agenda

Get in touch if you can play a part in next year’s event, particularly if you are willing to help make it be in-person!

How PAX6 gene deficiency affects your body
Professor Moosajee, Moorfields Eye Hospital

Woman wearing a white coats in a laboratory
Dr Mariya Moosajee

It is now accepted that reduced PAX6, caused by genetic changes involving this gene, does not just affect the eye (causing aniridia) but has an impact on many other organs of the body. In this talk, I will expand on the impact of PAX6 outside the eye, and expand on insights gained from looking at all the metabolites in the blood of aniridia patients (compared to unaffected age and gender matched control individuals).

Professor Mariya Moosajee is a clinician scientist, she is a Consultant Ophthalmologist specialising in Genetic Eye Disease and Head of the Genetics Service at Moorfields Eye Hospital, Professor of Molecular Ophthalmology at UCL Institute of Ophthalmology, and Group Leader of Ocular Genomics and Therapeutics at the Francis Crick Institute, London.
@MariyaMoosajee on Threads
@profmariya on Blue Sky

Samuel Heczko

Exploring PAX6 related gene regulatory networks & its role in the developing brain
Samuel Heczko & Dr. Wai Kit (Calvin) Chan, University of Edinburgh

We all come from a single cell. But how does this cell know when and how to divide into a brain? And how does the aniridia associated gene PAX6 guide this process?

Dr. Wai Kit Chan

Samuel is a Phd student of developmental neuroscience under the supervision of Dr Chan. Samuel on LinkedIn.

Dr. Wai Kit (Calvin) Chan is a Research Fellow at the Centre for Discovery Brain Sciences. His research focuses on the molecular and cellular mechanisms underlying forebrain development and pathology, particularly in the context of human neurodevelopmental disorders. He is currently investigating PAX6 haploinsufficiency using advanced organoid and assembloid models, employing techniques such as single-cell RNA sequencing, immunofluorescence, and electrophysiology.

Privilege, Protest. Power
Elliott Lee, person with aniridia

Identifying privilege, embracing protest, challenging power have all been integral to a journey these 25 years that I could not have imagined. Fighting for a seat at the table for the most marginalised has morphed into a passion, although that has only been possible through recognising my own vulnerabilities and taking part in civil resistance. Aniridia has shaped who I am, and I have driven that into a vision for a future that carries hope and dignity for all.

Elliott is a social activist and political campaigner who champions the most vulnerable. From a shy kid to a vocal advocate, he fearlessly confronts hate, the political status quo, and even has an arrest under his belt (From protesting). Mission? ensure every voice is given its place at the table.

Annual General Meeting 2025
Aniridia Network trustees

At the annual general meeting the trustee’s will seek approval of the minutes of last year’s meeting, then present highlights from the charity’s annual report, giving time for questions and comments. The results of the trustee election will also be announced.

Emily Nash

Can access to station information improve train travel for people with sight loss?
Emily Nash, Coventry University

My research is looking to identify and understand what barriers currently exist and find solutions to improve access. I will talk about how interviews and a usability study are helping achieve this.

Emily Nash lives in South Wales with her two children and they all have aniridia. Emily is currently completing a PhD in improving access to train travel for people with sight loss. She presented at the 2023 conference about her lived experience and the plans for her research.
Emily has been a member of Aniridia Network since 2015 and was a Trustee when she first joined.
Emily Nash on LinkedIn

John Brookes

Management of Glaucoma & Aniridia
Mr John Brookes, Moorfields Eye Hospital

A presentation about aniridia issues, particularly regarding how glaucoma is treated in children and adults with aniridia, from medical to laser and surgery.

Mr Brookes trained in London and qualified in 1993, subsequently specialising in ophthalmology and further, in paediatric glaucoma, for which he has been a consultant at Moorfields Eye Hospital since 2004. His main interest is in secondary glaucomas in children, such as aniridia and their surgical management


Posted in Aniridia Network news, Medical staff talking, Patients' tales, Research | Tagged , , , | Leave a comment

Annual General Meeting 2025

The Annual General Meeting (AGM) of Aniridia Network, a charitable incorporated organisation, was held online on Saturday 1 November at 2.40pm to transact the business below, in accordance with our governing document.

It was a session of Conference 2025, between interesting online seminars by patients and professionals.

Agenda

  1. Minutes of Annual General Meeting 2024 (see also video below)
  2. Matters arising
  3. Reports & Accounts – To receive and consider the:
  4. Announcement of the results of the online vote to re-appoint Andy Baghurst as a charity trustee until the 3rd AGM after this one, subject to the compulsory retirement of 1/3 of trustees by rotation at each AGM as described in the charity’s governing document.
  5. Any other business

Transcript

[James] Right, we are going to move on now to the formal part of proceedings. This is our annual general meeting of the charity Aniridia Network. And so I’m going to hand over to Andy to run this section.

[Andy] Thank you. Hello, good afternoon, everybody. So as James said, it’s the AGM now.

So the first thing that we need to do is approve the minutes of the last meeting. So these have been available on our website for a while, and were linked to in the notice of the meeting. And they’ve also been circulated in email newsletters and on social media.

If anyone has any comments on them, please raise them now. But if we don’t have any comments, we’ll take them as approved. So we’ll just give it a few seconds. And if no one starts to talk, we’ll take them as approved and then move on.

So I don’t think we’ve got any comments. So these are the key points that I want to draw attention to this year. So the annual report and accounts covers the period from 1st of April 2024 to 31st of March 2025.

We’re really grateful that two people in the year fundraised for us, and that somebody also has told us they will remember us by providing a legacy donation.

A number of events took place during the year, including the equivalent conference in July 2024. But we also hosted several in person meetups too.

During the year we moved our social media from Twitter/X to Threads and Blue Sky.

Membership of the charity has remained broadly steady, but we do struggle with a low number of volunteers. So if you do have any capacity to volunteer, no matter how much time you have, we’d be very grateful.

During the year, we also appointed some new medical advisors and developed our safeguarding policy and practices, not least so we stand ready to participate in future research, which researchers typically require from us.

We’ll start going through some of the detail. So during the year, we received three medical queries which covered a recommendation for an ophthalmologist in a specific place, a query about a link between an aniridia and another medical condition and a cataract operation on a toddler.

Our disability rights advisor didn’t receive any queries or requests for support, so just remember that that service is available should you require any advice.

In terms of befriending, we remain very grateful to Lyn for facilitating this for us. Six new buddy relationships were set up, four of which were for members with a newborn or child. Parent information packs were also sent to new members with children.

During the year, we received eight requests for education advice, with information sent including pupil passports and education health care plan resources, and one contact was from a school Senco.

So the conference, kindly organised by Tierney, was held online in July 2024, with recordings and transcriptions published online. There were a number of talks, including on how to support children with aniridia in education, as well as a talk on the development of eye drops to treat aniridia associated keratopathy.

Feedback from the conference was really positive, and so we are really grateful for that feedback, but also that people find it helpful.

So on Rare Disease Day, we held a number of meetups. So there were four cities, that hosted them, with eight members joining. And again, we got positive feedback.

So the seventh European Aniridia Conference took place during the year, with James and Katie going to the two day event in Stockholm, growing their knowledge and connecting with peers and professionals.

At the European Aniridia conference as well, the first leadership Academy took place and that was aimed at boosting young people’s confidence and creating future leaders for aniridia associations across Europe. We sponsored and supported Haya to take part, and she talked about it at last year’s online conference.

So we’ll now spend a couple of minutes talking about Aniridia Network’s finances. So our annual accounts, which I’ll talk through now, have been reviewed by and passed by an independent examiner.

As you may be able to see on screen, our bank balance grew over the year. So at year end, we had cash funds of just more than £57,000. We saw a significant uplift in donations during the year, and controlled costs by hosting the conference virtually. In the year, we spent about £2,500 and received income of just more than £11,000.

So on the screen now is a graph showing our expenditure for the year. So our biggest item of expenditure was grants to attend the European Aniridia Conference, followed by fundraising costs, which paid off as we saw the increase in donations. But the next biggest costs are running the website, as well as the independent examination of our accounts.

So this slide now covers income. So income for the year, as I mentioned, was just more than £11,000. Almost half of that came by JustGiving, with about 30% coming through CAF.

So a big thank you to everybody who donated and supported us through the year, we’re really very grateful. We don’t typically get funding from government or anything like that, so donations are important to enable us to do the things that we do.

Given our cash balance, we put some of the money in a high interest account, and earned more than £1,500 in interest.

So we’ll now move on to members and supporters. So we had 20 new or renewed members during the year, with members now just over 500, of which 161 are junior members. We also have the support of more than 230 people.

One of the challenges we do have is that when children become adults, we need them to re-register in their own right, which some aren’t doing, and we’re therefore considering a youth membership category to ease that transition.

As I mentioned earlier, we moved away from Twitter, or X as it’s now known I think. So please do follow us on our new channels. If you’d be interested in creating content for them, please do get in touch, as we would really value some help there.

Moving on, we’d particularly like to highlight a number of fantastic fundraisers over the year. So Gemma’s 3 Peaks challenge raised £735 and Jack’s marathon raised £3,080. Thanks very much to them and their sponsors. If you would like to fundraise through doing events, please do. And if you need some support from us, please do get in touch.

So our volunteer of the year is Tierney for arranging our online conference last year, including arranging the speakers, which is no mean feat. So a big thank you to Tierney for that.

We also want to say thank you to a number of other people who volunteered in different ways during the year. So those include Rachel, Simon, Glen, Lyn and Clive.

So again, as I mentioned earlier, we’ve appointed two new expert medical advisors in Professor Moosajee and Mr Brookes, who have both kindly joined us today. They are both consultant ophthalmologists at Moorfields Eye Hospital in London. If you do have any queries for them, do feel free to reach out to us and we can help facilitate that.

So I mentioned earlier that we have a low number of volunteers, notwithstanding the support that we did get. If you are interested in donating your time, we’d love to hear from you, no matter how much time you can give us. We could do with another trustee and volunteers to help with a wide range of things from member administration to communications and fundraising.

So that’s it from me. Unless there are any questions, I will hand back over to James.

[James] Yeah, are there any questions about what we’ve been up to in the last financial year or anything about the future for that matter?

[Anita] I just want to say thank you for all that you have done. It sounds as if you’ve been working really hard and amazing and very much appreciated.

[James] Ah, thank you. That’s very nice of you to say so. Cool, if there’s nothing else in the chat?

Okay, so yes, the last section here is the election. We have a rolling process, whereby every year we look to elect or re-elect our trustees, to make sure that you the members have a say in who’s leading the organisation.

And this year, it was Andy’s turn to be up for re-election, and he’s thankfully chosen to re-stand because he is our treasurer. So he keeps all our finances in order.

And so over the past one to two months, there has been an online election running, which many of you have taken part in, so thank you very much for that.

And I am pleased to say that using the online voting platform choice voting, that Andy received 32 votes in favour and zero, essentially, votes against for re-open nominations. So that’s excellent.

Andy’s actually done better than Katie and I previously, where we did get a couple of re-open nomination votes. So well done Andy, and congratulations and thank you.

[Andy] Thank you everybody.

[James] That was out of 434 voters though, so that’s just over 7% of you, the electorate. That’s also roughly, as you saw, the number of people with aniridia and parents with aniridia are the electorate there. So if anyone’s got ideas for increasing that number of participants, that would be good to hear. Perhaps we’ve got some more stuff to learn from from Elliott there in terms of profile and power and so on.

Right, next thing is a slightly last minute insertion. If I can hand over to Katie to talk a little bit about the European Aniridia Leadership and Collaboration Academy.

[Katie] Thanks James. So this is an exciting opportunity for some of you to participate in this Leadership and Collaboration Academy, which is taking place in Sofia in Bulgaria, the 17th to 19th of April 2026. So it’s taking place alongside the eighth European Aniridia Conference. And we’re looking for participants.

If you are a young person, which is quite a broad definition of young, so 18 to 40, who’s looking to build their self confidence, their interpersonal skills, their ability to organise people and projects, as well as building your aniridia knowledge through participating in practical workshops, and hearing from inspiring leaders who will guide you through developing ideas, which will benefit you and the aniridia community, and help you to build connections with a range of professionals from around the world, many of whom have Aniridia.

If that sounds exciting, that’s something you’d want to participation in, as I say we’re looking for people between the ages of 18 and 40, who have any sort of connection with aniridia. So it could be having aniridia yourself, but it could be being a parent of a child with aniridia, it could have be a sibling or a friend who has aniridia, or just a professional interest through your profession.

If this interests you and you’d like to take part, we will be funding people from the UK who would like to participate. So we really encourage you to get in touch if this sounds like something that’s exciting to you.

If you were interested in developing your own skills, helping other people, and you want to contribute to the success of Aniridia Network or Aniridia Europe, please get in touch with us.

And look out for more information, it will be coming soon. So yeah, make sure that you’re getting our email newsletters and following us on social media, etc.

[James] Yeah, brilliant. So yes, if you fancy coming along with us, Katie and myself will be going to Sofia in Bulgaria in April. So if you’d like to come along with us, it is a brilliant experience going to the European Aniridia Conference.

There are lots of people with aniridia there from all over the continent, and many clinicians and scientists, so people like Mariya Moosajee, who we mentioned earlier, is often there for example, and many others like them.

And yeah, it was brilliant when we did this Leadership Academy one and a half years ago, myself, Katie and several other people spoke at that. And again, it was a really good opportunity to meet with the young people there and to get them involved and understanding more about the community and so on.

So yeah, if this interests you at all, please do get in touch. Use our usual contact address, so info@aniridia.org.uk, for example. If you prefer to use Facebook or whatever, that’s fine as well.

So we’ll put out more information, we more just wanted to take this opportunity to advertise it. The exact application process hasn’t exactly been decided yet. But we wanted to make you aware of this now. So if you get in touch, you will actually almost help shape what that application process is. So this is an opportunity in and of itself to get involved.

So yeah, please do speak to your relatives and so on, if this sounds like something they would like to get involved with, through you.

Posted in Aniridia Network news | Tagged , , , , , | 2 Comments